JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

CareDx Inc

Закрыт

СекторЗдравоохранение

20.78 -0.38

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

20.23

Макс.

21.68

Ключевые показатели

By Trading Economics

Доход

-5.8M

-4.1M

Продажи

8.3M

108M

P/E

Средняя по отрасли

14.645

67.147

Прибыль на акцию

0.12

Рентабельность продаж

-3.79

Сотрудники

761

EBITDA

-5.7M

1.5M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+18.89% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

119M

1.1B

Предыдущая цена открытия

21.16

Предыдущая цена закрытия

20.78

Новостные настроения

By Acuity

65%

35%

314 / 347 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Neutral Evidence

CareDx Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 апр. 2026 г., 23:08 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 23:07 UTC

Отчет

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:20 UTC

Отчет

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 апр. 2026 г., 23:27 UTC

Обсуждения рынка

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 апр. 2026 г., 23:22 UTC

Отчет

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 апр. 2026 г., 23:20 UTC

Обсуждения рынка

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 апр. 2026 г., 22:52 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:33 UTC

Отчет

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 апр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 апр. 2026 г., 22:05 UTC

Отчет

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 21:57 UTC

Отчет

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 апр. 2026 г., 21:55 UTC

Отчет

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 апр. 2026 г., 21:53 UTC

Отчет

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение c конкурентами

Изменение цены

CareDx Inc Прогноз

Целевая цена

By TipRanks

18.89% рост

Прогноз на 12 месяцев

Средняя 24.73 USD  18.89%

Максимум 28 USD

Минимум 21 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для CareDx Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

2

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

14.77 / 18.49Поддержка и Сопротивление

Краткосрочная

Neutral Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

314 / 347Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat